semaglutide fda warning Clears For Cardiac Risk Reduction in Diabetic Patients FDA adds warning for intestinal

Up to 63% of type 2 diabetes patients on GLP-1 RAs reach healthy blood sugar levels after at least 12 weeks

Exposure to phthalates and breast cancer risk in northern Mexico

Surgical versus non-surgical treatment for acute Achilles' tendon rupture

Data were extracted as follows: (1) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), fetal effects of maternal GLP-1 agonist or SGLT2 inhibitor exposure, (2) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), the transfer of GLP-1 agonist or SGLT2 inhibitor in maternal milk and the effect of exposure during lactation on the neonate